Gout Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

Gout Market Report Overview

The Gout market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $4.63 billion in 2022. Significant growth is expected at a CAGR of more than 8% from 2022 to 2032 as the gout population steadily increases and novel therapies enter the market. The US had the highest number of diagnosed prevalent cases of gout in 2022, followed by France and the UK.

Gout is a form of arthritis that causes pain and discomfort in the joints. A typical gout attack is characterized by the sudden onset of severe pain, swelling, warmth, and redness of a joint. Acute gout, also referred to as asymptomatic hyperuricemia, is a painful condition that often affects only one joint (monoarticular) and is likely to occur due to a period of high meat and alcohol consumption and can dissipate over time.

Gout Market Outlook 2022-2032 ($ Billion)

Buy the Full Report to Know More About the Gout Market Forecast
Download a Free Sample Report

The Gout market research report offers an overview of Gout, including its epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying smart business strategies. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.

Gout Market Dynamics

Currently, the treatment regimen for gout in the 7MM is mostly limited to NSAIDs, corticosteroids, and urate-lowering therapies (ULTs) with challenging safety profiles, such as allopurinol. The uptake of therapies in the gout pipeline by physicians will be driven by clinical data demonstrating efficacy. If a novel ULT therapy can demonstrate significant efficacy in treating chronic gout cases in adults and elderly patients, it will obtain a large market share. Moreover, there is a pressing need for improved therapies for severe gout patients. For this purpose, therapies with novel mechanisms of action (MoAs) are required, with improved efficacy, to address the significant market gap in treating severe gout and persistently high uric acid levels as found in refractory gout.

Buy the full Report for Additional Insights on the Key Gout Market Dynamics, Download a Free Sample Report

Gout Market Segmentation by Country

The key countries in the Gout market are the US, 5EU, and Japan. In 2022, the US dominated the total Gout market share. The US market dominance within the 7MM is due to the higher price of pharmaceuticals in the US and the high diagnosed prevalence of gout in the country compared to the other major markets.

Gout Market Analysis by Country, 2022 (%)

Buy the Full Report for Country-Wise Insights on the Gout Market, Download a Free Sample Report

Gout Market Segmentation by Drug Classes

During 2022, there were several drug classes in the Gout market: Anti-inflammatory therapies for acute attacks and those for prophylaxis and ULTs. Multiple generic NSAIDs and corticosteroid therapies are marketed in the anti-inflammatories class, along with the branded therapy Ilaris. Several therapies, including dapansutrile, canakinumab (biosimilar), pegloticase (biosimilar), dotinurad (pediatric use), pegadricase, and tigulixostat, are expected to launch in the later years of the forecast period.

Gout Market Analysis by Drug Classes, 2022 (%)

Buy the Full Report for Drug-Class Insights on the Gout Market, Download a Free Sample Report

Gout Market Segmentation by Sponsors

The key sponsors in the Gout market are Horizon Therapeutics USA Inc, Teijin Pharma Ltd, Fuji Yakuhin Co Ltd, Lipomed AG, and Novartis AG among others.

Gout Market Analysis by Sponsors

Buy the Full Report for Sponsor-Wise Insights on the Gout Market, Download a Free Sample Report

Segments Covered in this Report

Gout Country Outlook ($ Billion, 2022-2032)

• The US
• 5EU
• Japan

Gout Drugs Outlook (%, 2022-2032)

• NSAIDs
• Colchicine
• Oral Corticosteroids
• Corticosteroid Injections
• Ilaris
• Allopurinol

Scope

• Overview of Gout, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Gout treatment market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Gout therapeutics market.
• Pipeline analysis, comprehensive data assessing emerging trends, and mechanisms of action under development for Gout treatment. The most promising candidates in the late stage of development are profiled.
• Analysis of the current and future market competition in the 7MM Gout therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model.

Forecast includes US, 5EU, and Japan [5EU (France, Germany, Italy, Spain, and the UK) were forecasted as one entity]

Forecasts cover 2022-2032.

Reasons to Buy

• Review the pipeline products and technologies and identify the companies with the most robust pipeline to develop and design your in-licensing and out-licensing strategies.
• Understand the trends shaping and driving the GD therapeutics market to develop business strategies.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.